MAIA Biotechnology Inc

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $1.00 Million Private Placement.

MAIA Biotechnology Announces $1.00 Million Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Two Investor Conferences in April 2024.

MAIA Biotechnology to Present at Two Investor Conferences in April 2024

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero.

MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement.

MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $1.33 Million Private Placement.

MAIA Biotechnology Announces $1.33 Million Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement.

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board.

MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Participate in the 36th Annual ROTH Conference.

MAIA Biotechnology to Participate in the 36th Annual ROTH Conference

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at AACR Annual Meeting.

MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients.

MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders.

MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders

CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

CHICAGO, IL, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that enrollment is now complete in its Phase 2 THIO-101 go-to-market clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC).

MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer.

MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds.

MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds

MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.

MAIA Soars 20% on Interim Results From Lung Cancer Study

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024.

MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024.

MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024

Lead asset THIO has a unique telomere-targeting mechanism and has reported impressive preliminary results in NSCLC. THIO's 90%+ disease control rate in second- and third-line NSCLC is an improvement over current standard of care. Plans to pursue accelerated approval in NSCLC in 2025 and has the potential to become a new standard of care.

MAIA Biotechnology: Significantly Undervalued With Novel Mechanism And Impressive Early Data

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer.

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. (MAIA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Bears are Losing Control Over MAIA Biotechnology, Inc. (MAIA), Here's Why It's a 'Buy' Now

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering.

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

CHICAGO, IL / ACCESSWIRE / November 17, 2023 / More than 300,000 people are diagnosed with brain cancer across the globe each year. Glioblastoma represents the majority of these cases in the U.S., with 15,000 new patients diagnosed and more than 10,000 deaths annually.

MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $4 Million Registered Direct Offering.

MAIA Biotechnology Announces $4 Million Registered Direct Offering

CHICAGO--(BUSINESS WIRE)--FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma.

News for MAIA Biotechnology Inc Stock (MAIA)